Agency
Planned Parenthood of Michigan
Planned Parenthood of Michigan was paid $11.16M by Medicaid between Jan 2018 and Dec 2024, across 41 billing codes. Its largest line is J7307, Etonogestrel (contraceptive) implant system, including implant and supplies — 21% of everything it billed.
33Billing provider infoPLANNED PARENTHOOD OF MICHIGAN
ANN ARBOR, MI 48104
ANN ARBOR, MI 48104
33aNPI1366525370assigned 10/23/2006
33bProvider typePublic Health or Welfare Agency
28Total paid$11.16M
24GClaims272,615
24DCodes billed41
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Public Health or Welfare Agency providers in Michigan
Rank by total paid#3 of 58
Median peer was paid$221K
This provider vs. median50×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,801 | $2.04M | |
| 2019 | 43,361 | $1.81M | |
| 2020 | 28,529 | $942K | |
| 2021 | 34,090 | $1.28M | |
| 2022 | 40,742 | $1.64M | |
| 2023 | 43,420 | $1.88M | |
| 2024incomplete | 33,672 | $1.57M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 21% | 5,080 | 5,067 | $2.39M |
| S4993 | Contraceptive pills for birth control | 14% | 18,908 | 18,394 | $1.61M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 25,640 | 25,092 | $1.16M |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 7.5% | 2,166 | 2,155 | $838K |
| J7300 | Intrauterine copper contraceptive (paragard) | 5.9% | 2,052 | 2,042 | $657K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 5.3% | 14,600 | 14,526 | $596K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 4.9% | 27,331 | 27,242 | $543K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 3.8% | 13,576 | 13,393 | $427K |
| 58300 | 2.7% | 5,586 | 5,458 | $306K | |
| 11981 | 2.5% | 4,307 | 4,297 | $277K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.3% | 4,107 | 4,100 | $260K |
| 81025 | 2.1% | 35,805 | 34,920 | $238K |
29 more codes
| 11982 | 2.1% | 3,218 | $229K | |
| 86703 | 2.0% | 20,851 | $224K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.8% | 2,545 | $201K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 20,426 | $174K |
| 58301 | 1.6% | 2,985 | $173K | |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.3% | 2,171 | $146K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 1,341 | $131K |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | 1.2% | 1,427 | $130K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.2% | 10,778 | $130K |
| 99385 | 1.1% | 1,235 | $119K | |
| 87210 | <1% | 16,995 | $76K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 535 | $41K |
| 11983 | <1% | 403 | $36K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,175 | $21K |
| 81002 | <1% | 4,317 | $12K | |
| 99201 | <1% | 432 | $10K | |
| J7295 | Ethinyl estradiol and etonogestrel 0.015mg, 0.12mg per 24 hours; monthly vaginal ring, each | <1% | 180 | $6K |
| 85018 | <1% | 1,743 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 121 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 115 | $2K |
| 56501 | <1% | 12 | $1K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 13 | $1K |
| 81000 | <1% | 274 | $801.03 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $607.38 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 531 | $342.36 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24 | $133.00 |
| 86901 | <1% | 13 | $21.62 | |
| 36416 | <1% | 1,490 | $21.25 | |
| 99000 | 0% | 13,094 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOVIN, KIMBERLY (DIRECTOR OF REVENUE CYCLE)